145 related articles for article (PubMed ID: 37356987)
21. Unraveling the Mystery of Gray Zone Lymphoma in Human Immunodeficiency Virus-Seropositive Patients: Two Cases.
Ahluwalia A; Bondili L; Salamera J; Cholankeril M
J Hematol; 2020 Dec; 9(4):132-136. PubMed ID: 33224393
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy and prognostic analysis of 98 cases of relapsed/refractory diffuse large B-cell lymphoma treated with second-line regimens].
Zhang MC; Qian Y; Hao J; Liu ZY; Zhao WL; Wang L
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):511-516. PubMed ID: 28655095
[No Abstract] [Full Text] [Related]
23. Mutational landscape of gray zone lymphoma.
Sarkozy C; Hung SS; Chavez EA; Duns G; Takata K; Chong LC; Aoki T; Jiang A; Miyata-Takata T; Telenius A; Slack GW; Molina TJ; Ben-Neriah S; Farinha P; Dartigues P; Damotte D; Mottok A; Salles GA; Casasnovas RO; Savage KJ; Laurent C; Scott DW; Traverse-Glehen A; Steidl C
Blood; 2021 Apr; 137(13):1765-1776. PubMed ID: 32961552
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.
Pilichowska M; Pittaluga S; Ferry JA; Hemminger J; Chang H; Kanakry JA; Sehn LH; Feldman T; Abramson JS; Kritharis A; Hernandez-Ilizaliturri FJ; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA; Jagadeesh D; Woda B; Gupta GK; Gascoyne RD; Jaffe ES; Evens AM
Blood Adv; 2017 Dec; 1(26):2600-2609. PubMed ID: 29296913
[TBL] [Abstract][Full Text] [Related]
25. Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report.
Hojo N; Nagasaki M; Mihara Y
World J Clin Cases; 2022 Jun; 10(17):5708-5716. PubMed ID: 35979119
[TBL] [Abstract][Full Text] [Related]
26. Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA.
Sarkozy C; Copie-Bergman C; Damotte D; Ben-Neriah S; Burroni B; Cornillon J; Lemal R; Golfier C; Fabiani B; Chassagne-Clément C; Parrens M; Herbaux C; Xerri L; Bossard C; Laurent C; Cheminant M; Cartron G; Cabecadas J; Molina T; Salles G; Steidl C; Ghesquières H; Mottok A; Traverse-Glehen A
Am J Surg Pathol; 2019 Mar; 43(3):341-351. PubMed ID: 30540571
[TBL] [Abstract][Full Text] [Related]
27. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
[TBL] [Abstract][Full Text] [Related]
28. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
29. Gene expression profiling of gray zone lymphoma.
Sarkozy C; Chong L; Takata K; Chavez EA; Miyata-Takata T; Duns G; Telenius A; Boyle M; Slack GW; Laurent C; Farinha P; Molina TJ; Copie-Bergman C; Damotte D; Salles GA; Mottok A; Savage KJ; Scott DW; Traverse-Glehen A; Steidl C
Blood Adv; 2020 Jun; 4(11):2523-2535. PubMed ID: 32516416
[TBL] [Abstract][Full Text] [Related]
30. Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission.
Terao T; Yuda J; Yamauchi N; Guo YM; Shimada K; Sugano M; Ishii G; Minami Y
Mol Clin Oncol; 2021 Jun; 14(6):125. PubMed ID: 33936598
[TBL] [Abstract][Full Text] [Related]
31. Pediatric gray zone lymphoma according to the 2022 WHO classification: An Italian cohort study.
Restivo GA; Farruggia P; Pillon M; Mascarin M; Elia C; Recupero S; Muggeo P; Cagnazzo C; Onofrillo D; Mura R; Furfari I; Trizzino A; Bertolini P; Sala A; De Santis R; Galimberti D; Schiavello E; Carraro E;
Pediatr Blood Cancer; 2023 May; ():e30481. PubMed ID: 37254478
[TBL] [Abstract][Full Text] [Related]
32. Gray-zone lymphoma. Examples of rare clinical manifestation.
Misyurina AE; Kravchenko SK; Mangasarova YK; Magomedova AU; Kovrigina AM; Shimanovskaya LT; Fastova EA; Misyurin VA; Model SV; Chebotarev DI; Kostina IE; Savchenko VG
Ter Arkh; 2019 May; 91(4):107-113. PubMed ID: 31094484
[TBL] [Abstract][Full Text] [Related]
33. [Dose-intensive immunochemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of 29 newly diagnosed young patients with medium/high risk diffuse large B-cell lymphoma].
Yi S; Liu W; Lyu R; Li Z; Xu Y; Sui W; Huang W; Wang T; Deng S; Liu H; Fu M; Zou D; Qiu L
Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):546-50. PubMed ID: 24985182
[TBL] [Abstract][Full Text] [Related]
34. [Clinical pathologic characteristics and treatment outcomes of 19 relapsed pediatric B-cell lymphoma].
Huang S; Jin L; Yang J; Duan YL; Zhang M; Zhou CJ; Ma XL; Zhang YH
Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):748-753. PubMed ID: 29050112
[No Abstract] [Full Text] [Related]
35. [Clinical Analysis of 153 Cases of Refractory/Relapsed Diffuse Large B-cell Lymphoma].
Zou DD; Guo B; Yin P; Tian Y; Zhu HL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):120-125. PubMed ID: 28245387
[TBL] [Abstract][Full Text] [Related]
36. Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens.
Villela L; López-Guillermo A; Montoto S; Rives S; Bosch F; Perales M; Ferrer A; Esteve J; Colomo L; Campo E; Montserrat E
Cancer; 2001 Apr; 91(8):1557-62. PubMed ID: 11301405
[TBL] [Abstract][Full Text] [Related]
37. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
Ayers EC; Li S; Medeiros LJ; Bond DA; Maddocks KJ; Torka P; Mier Hicks A; Curry M; Wagner-Johnston ND; Karmali R; Behdad A; Fakhri B; Kahl BS; Churnetski MC; Cohen JB; Reddy NM; Modi D; Ramchandren R; Howlett C; Leslie LA; Cytryn S; Diefenbach CS; Faramand R; Chavez JC; Olszewski AJ; Liu Y; Barta SK; Mukhija D; Hill BT; Ma H; Amengual JE; Nathan S; Assouline SE; Orellana-Noia VM; Portell CA; Chandar A; David KA; Giri A; Hess BT; Landsburg DJ
Cancer; 2020 Jan; 126(2):293-303. PubMed ID: 31568564
[TBL] [Abstract][Full Text] [Related]
38. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma.
Traverse-Glehen A; Pittaluga S; Gaulard P; Sorbara L; Alonso MA; Raffeld M; Jaffe ES
Am J Surg Pathol; 2005 Nov; 29(11):1411-21. PubMed ID: 16224207
[TBL] [Abstract][Full Text] [Related]
39. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
[TBL] [Abstract][Full Text] [Related]
40. Mediastinal large B cell lymphoma and surrounding gray areas: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology.
Gibson SE; Dojcinov S; Dotlic S; Hartmann S; Hsi ED; Klimkowska M; Melle F; Pileri SA; Ramsower CA; Rech K; Rimsza LM; Rodriguez-Pinilla SM; Tousseyn TA; de Jong D; Sabattini E
Virchows Arch; 2023 Dec; 483(6):733-749. PubMed ID: 37530791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
